Published in Support Care Cancer on September 27, 2014
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet (2000) 4.38
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med (2013) 3.40
A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg (2006) 2.97
Evaluation of surveillance bias and the validity of the venous thromboembolism quality measure. JAMA (2013) 2.31
Patient readmission and mortality after colorectal surgery for colon cancer: impact of length of stay relative to other clinical factors. J Am Coll Surg (2012) 2.29
The occurrence of venous thromboembolism in cancer patients following major surgery. Thromb Res (2012) 1.53
Readmission rates after abdominal surgery: the role of surgeon, primary caregiver, home health, and subacute rehab. Ann Surg (2011) 1.52
Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med (2004) 1.26
Hospital performance measures and 30-day readmission rates. J Gen Intern Med (2012) 1.23
Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev (2009) 1.17
Cancer-associated thrombosis: updates and controversies. Hematology Am Soc Hematol Educ Program (2012) 1.08
Timing and perioperative risk factors for in-hospital and post-discharge venous thromboembolism after colorectal cancer resection. Clin Appl Thromb Hemost (2012) 0.91
Extended perioperative thromboprophylaxis in patients with cancer. A systematic review. Thromb Haemost (2008) 0.88
Cost-effectiveness of prolonged thromboprophylaxis after cancer surgery. Ann Surg Oncol (2009) 0.88
Prevention of venous thromboembolism after surgery. Cleve Clin J Med (2009) 0.83
Deep venous thrombosis after general surgical operations at a university hospital: two-year data from the ACS NSQIP. Arch Surg (2011) 0.81
Readmissions after pancreaticoduodenectomy: efforts need to focus on patient expectations and nonhospital medical care. Am Surg (2012) 0.80
Thromboprophylaxis following surgery for colorectal cancer - is it worthwhile after hospital discharge? Scand J Surg (2009) 0.78
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (2008) 3.74
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol (2012) 2.15
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood (2009) 2.07
Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol (2009) 1.77
Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol (2004) 1.69
Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. Leuk Lymphoma (2012) 1.48
Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care (2005) 1.23
Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol (2008) 1.20
Automated mapping of social networks in wild birds. Curr Biol (2012) 1.17
Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther (2006) 1.15
Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer (2008) 1.09
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J Infect Dis (2005) 1.07
Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. PLoS Pathog (2013) 1.04
High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol (2008) 1.03
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol (2012) 0.94
Preoperative use of recombinant human erythropoietin before total joint arthroplasty. J Bone Joint Surg Am (2003) 0.91
Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol (2005) 0.87
Blood management in total joint arthroplasty. Am J Orthop (Belle Mead NJ) (2006) 0.85
Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role? Semin Dial (2008) 0.84
Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol (2004) 0.82
Pharmacovigilance in practice: erythropoiesis-stimulating agents. Cancer Med (2014) 0.77
The assessment of thrombotic risk using a predictive model in metastatic cancer patients undergoing first-line therapy. Thromb Res (2012) 0.75
Increased importance of intravenous iron in chemotherapy-induced anemia. J Clin Oncol (2007) 0.75
Guidelines for the use of epoetin in cancer patients: a much-needed step forward in standardizing anemia treatment. Blood (2003) 0.75